With the rapidly evolving of
immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various
cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing
immunotherapy. There are limited data about
immunotherapy re-challenge in patients with renal clear cell
cancer who had irAE in the initial ICI
therapy. In this study, we reported the case of a patient with advanced renal clear cell
cancer who developed serious irAEs but also achieved a partial remission of
tumor after ICI combined with
pazopanib in the first-line treatment. After intravenous
methylprednisolone therapy for two weeks, the patient fully recovered from treatment-related toxicities. After a multidisciplinary treatment (MDT) discussion and a communication with the patient, the decision was made to undergo a new fully humanized programmed death 1 (PD-1) agent,
zimberelimab, combined with
pazopanib for immune restart
therapy. After two cycles of treatment, the patient demonstrated a partial response (PR), and the disease remained in continuous remission without any irAE at our last follow-up after 14 months' treatment. Re-challenging with
immunotherapy after irAEs is an emerging strategy that offers the potential for additional clinical benefits to previously responding patients. However, careful patient selection and monitoring are essential to maximize the safety and efficacy of this approach.